Keywords: Amarin, AMR101, Cholesterol, Fish oils, GlaxoSmithKline, Lovaza
Amarin will apply for approval of cholesterol drug candidate AMR101 earlier on strong Ph III results
Article | 30 November 2010
US/Irish biopharmaceutical firm Amarin (Nasdaq: AMRN), yesterday reported positive, statistically significant top-line results from the MARINE study, its first ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
